Form 4: Zevra Director Boosts Stake with $45K Stock Buy

Zevra Therapeutics Director John B. Bode acquired 5,000 shares of common stock for $9.165 each, increasing his total beneficial ownership to 45,000 shares.

Summary

• John B. Bode, a Director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 5,000 shares of the company's common stock.
• The transaction occurred on August 19, 2025, at a price of $9.165 per share.
• Following this acquisition, Mr. Bode's total beneficial ownership of Zevra Therapeutics common stock increased to 45,000 shares.
• The purchase was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: The insider purchase by a director is a positive signal, indicating confidence in the company's value and future prospects. While not a 'strong buy' signal on its own, it adds to positive sentiment.

Positives

• A company director, John B. Bode, increased his stake in Zevra Therapeutics by purchasing 5,000 shares, signaling confidence in the company's future prospects.
• The acquisition increases the director's total beneficial ownership to 45,000 shares, aligning his interests further with shareholders.

Future Outlook

The transaction, executed under a Rule 10b5-1 plan, indicates a pre-scheduled purchase by a director, reflecting a long-term investment strategy rather than a reaction to immediate market events.

Industry Context

Insider purchases, particularly by directors, are often viewed positively in the biotechnology and pharmaceutical sectors as they can indicate management's belief in the company's pipeline, strategic direction, or undervaluation, especially given the inherent risks and long development cycles in the industry.

Corporate Governance

Related Party Transactions

• The purchase of 5,000 shares of common stock by John B. Bode, a Director of Zevra Therapeutics, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The insider purchase may instill greater confidence among existing and potential shareholders, as it signals management's belief in the company's value and future performance.
• Employees: May positively impact employee morale by demonstrating leadership's commitment and belief in the company's direction.

Key Dates

Recommendation

The insider purchase by a director is a positive indicator, suggesting confidence in the company's valuation and future. However, a single insider transaction, even by a director, typically warrants a 'hold' recommendation rather than a 'buy' unless supported by other strong fundamental or technical indicators. It's a favorable data point but not a standalone catalyst for a strong buy.

Keywords

ZEVRA THERAPEUTICS, ZVRA, insider trading, Form 4, stock purchase, director, common stock, beneficial ownership, 10b5-1 plan